Dr. Scott Aaronson is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine, distinguished life fellow of the American Psychiatric Association, and is a fellow of the American College of Psychiatrists. Dr. Aaronson also serves on the boards of the American Society of Clinical Psychopharmacology and the Clinical TMS Society.
In addition to his work at The Retreat, Dr. Aaronson is the director of clinical research programs at Sheppard Pratt, where he is the principal investigator for multiple studies on the development of therapies for mood and anxiety disorders. He has particularly been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS) and Vagus Nerve Stimulation (VNS)—in the treatment of severe refractory mood disorders. Most recently, he was named the Chief Science Officer of the Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics, focused on the development of uses for psychedelic medications across the spectrum of psychiatric illness.
Harvard Medical School
McLean Hospital; Harvard University Health Services
Harvard Medical School - Sleep Physiology
- General Psychiatry
- Forensic Medicine
- Distinguished Fellow, American Psychiatric Association
- Member, American College of Psychiatrists
- Member, Maryland Psychiatric Society
- Member, Society of Biological Psychiatry
- Member, American College of Psychiatrists
- Member, American Society for Clinical Psychopharmacology
- Member, International Society of ECT and Neurostimulation
- Member, Clinical TMS Society
Garakani, Amir MD; Alexander, Jeanne L. MD; Sumner, Calvin R. MD; Pine, Janet H. MD; Gross, Lawrence S. MD; Raison, Charles L. MD; Aaronson, Scott T. MD; Baron, David A. DO. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal of Psychiatric Practice 29(5):p 345-353, September 2023. DOI: 10.1097/PRA.0000000000000729
Sackheim, H.A., Aaronson, S.T., Bunker, M.T., Conway, C.R., Demitrack, M.A., George, M.S., Prudic, J., Thas, M.E., Rush, A.J. (2019). The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). Journal of Psychiatric Research, 113, 125–136. doi: 10.1016/j.jpsychires.2019.03.021
Scott T. Aaronson & Maria Mouratidis (2019) The Evolving Concept of a Therapeutic Community, Psychiatry, DOI: 10.1080/00332747.2019.1565557
Kumar, A., Bunker, M.T., Aaronson, S.T., Conway, C.R., Rothschild, A.J., Mordenti, G., Rush, A.J. (2019). Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression. Neuropsychiatric Disease and Treatment, Volume 15, 457–468. doi: 10.2147/ndt.s19666
Rush, A.J., Aaronson, S.T., Demyttenaere, K. Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive, Aust N Z J Psychiatry. 2019 Feb;53(2):109-118. doi: 10.1177/0004867418808585. Epub 2018 Oct 31.
Aaronson ST, Conway CR. Vagus Nerve Stimulation: Changing the Paradigm for Chronic Severe Depression? Psychiatr Clin North Am. 2018 Sep;41(3):409-418. doi: 10.1016/j.psc.2018.05.001. Review. PubMed PMID: 30098654.
Conway CR, Kumar A, Xiong W, Bunker M, Aaronson ST, Rush AJ. Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. J Clin Psychiatry. 2018 Aug 21;79(5). pii: 18m12178. doi:10.4088/JCP.18m12178. PubMed PMID: 30152645
Martin DM, McClintock SM, Aaronson ST, Alonzo A, Husain MM, Lisanby SH,McDonald WM, Mohan A, Nikolin S, O'Reardon J, Weickert CS, Loo CK. Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial. Brain Stimul. 2018 Aug 23. pii: S1935-861X(18)30294-8. doi:10.1016/j.brs.2018.08.011. [Epub ahead of print] PubMed PMID: 30172724.
Aaronson ST, Croarkin PE. Neurostimulation. In: Black DW, ed. Scientific American Psychiatry. Hamilton: Decker; July 2018. DOI: 10.2310/7800.13082.
Aaronson ST, Philip NS. Neuromodulation. Psychiatr Clin North Am. 2018Sep;41(3):xiii-xvi. doi: 10.1016/j.psc.2018.06.001. Epub 2018 Jul 17. PubMed PMID: 30098663.
Kavanaugh BC, Aaronson ST, Clarke GN, Holtzheimer PE, Johnson CW, McDonald WM, Schneider MB, Carpenter LL. Neurocognitive Effects of Repetitive Transcranial Magnetic Stimulation with a 2-Coil Device in Treatment-Resistant Major Depressive Disorder. J ECT. 2018 Apr 2. doi: 10.1097/YCT.0000000000000494. [Epub ahead of print] PubMed PMID: 29613944.
Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial. JAMA Psychiatry. 2023 Dec 6. doi: 10.1001/jamapsychiatry.2023.4685. Epub ahead of print. PMID: 38055270.